
Jazz swings further into cancer with Chimerix takeover
Jazz Pharmaceuticals has reached an agreement to buy Nasdaq-listed Chimerix for around $935 million, adding a brain cancer drug that is heading for an FDA verdict in the summer. The Irish and US pharma group is offering $8.55 per share in cash for Chimerix …